Another HDAC6 inhibitor, ACY-1215, which is in a phase 2 clinical trial for multiple myeloma, has high HDAC6 enzyme potency but low isotype selectivity (11-fold selectivity for HDAC6 and HDAC1 at IC50)27. The gene discussed is HDAC6; the disease is plasma cell myeloma.